The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets-Reference-Cited by-同舟云学术

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

Published:2023-07 Issue:3 Volume:152 Page:193-199
ISSN:1347-8613
Container-title:Journal of Pharmacological Sciences
language:en
Short-container-title:Journal of Pharmacological Sciences

Author:

Ohno Yutaro,Okita Eri,Kawai-Uchida Mika,Shoukei Youji,Soshiroda Kazuhiro,Kanda Tomoyuki,Uchida Shinichi^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,Molecular Medicine

Reference37 articles.

1. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications;Kish;N Engl J Med,1988

2. Parkinson's disease;Lees;Lancet,2009

3. The history of dopamine and levodopa in the treatment of Parkinson's disease;Fahn;Mov Disord,2008

4. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease;You;Cell Tissue Res,2018

5. Role of pramipexole in the management of Parkinson's disease;Antonini;CNS Drugs,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics of the Novel Adenosine A_2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease;Clinical Pharmacology in Drug Development;2024-01-04

2. Pharmacology of Adenosine Receptors: Recent Advancements;Biomolecules;2023-09-14

3. A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists;International Review of Neurobiology;2023